Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high‐risk myelodysplastic syndromes: Challenges and opportunities in implementation-Reference-Cited by-同舟云学术

Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high‐risk myelodysplastic syndromes: Challenges and opportunities in implementation

Published:2021-08-10 Issue:23 Volume:127 Page:4339-4347
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Warlick Erica D.¹^ORCID,Ustun Celalettin²,Andreescu Astrid³,Bonagura Anthony F.⁴,Brunner Andrew⁵,Chandra Abhinav B.⁶,Foran James M.⁷^ORCID,Juckett Mark B.⁸,Kindwall‐Keller Tamila L.⁹,Klimek Virginia M.¹⁰,Pease Daniel F.¹¹,Steensma David P.¹²,Waldman Bryce M.¹³,Horowitz Mary M.¹³¹⁴,Burns Linda J.¹³,Khera Nandita¹⁵^ORCID

Affiliation:

1. Division of Hematology, Oncology, and Transplantation University of Minnesota Minneapolis Minnesota

2. Rush University Medical Center Chicago Illinois

3. Northern Light Eastern Maine Medical CenterLafayette Family Cancer Institute Bangor Maine

4. Optum North Wales Pennsylvania

5. Massachusetts General Hospital Boston Massachusetts

6. Yuma Regional Medical Center Yuma Arizona

7. Mayo Clinic Cancer CenterMayo Clinic Jacksonville Florida

8. School of Medicine and Public Health University of Wisconsin Madison Wisconsin

9. University of Virginia Charlottesville Virginia

10. Memorial Sloan Kettering Cancer Center New York New York

11. Hennepin Healthcare Minneapolis Minnesota

12. Dana‐Farber Cancer Institute Boston Massachusetts

13. Center for International Blood and Marrow Transplant Milwaukee Wisconsin

14. Medical College of Wisconsin Milwaukee Wisconsin

15. College of Medicine Mayo Clinic Phoenix Arizona

Funder

National Heart, Lung, and Blood Institute

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33826

Reference44 articles.

1. Treatment of MDS

2. Revised International Prognostic Scoring System for Myelodysplastic Syndromes

3. Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys

4. Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50 to 75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 Study Rationale, Design, and Methods

5. Allogeneic Hematopoietic Stem Cell Transplant for MDS;2021. Centers for Medicare & Medicaid Services.https://www.cms.gov/Medicare/Coverage/Coverage‐with‐Evidence‐Development/allo‐HSCT

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy?;Blood Reviews;2023-07

2. Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS);Blood Cancer Journal;2022-11-15

3. Transplantation provides superior survival high risk myeloid malignancies in older patients;Leukemia & Lymphoma;2022-05-19